Developer docs
API playgroundTry for free, no card

Search company profiles

Index Capital

Full company profile

uuid000d7vw

Namestring
Index Capital
Legal namestring
指数资本
Websiteurl
indexvc.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Index Capital (指数资本) is a China-based boutique full-stack investment bank (投行) founded in 2014 and headquartered in Shanghai with a regional office in Beijing. The firm provides financial advisory services to innovative technology enterprises, specializing in financing rounds, M&A transactions, IPO advisory, and debt financing. Across sectors including AI, biotech, quantum computing, semiconductors, advanced manufacturing, new energy, and the low-altitude economy, the firm has completed over 100 financing transactions since 2018. Notable mandates include the exclusive financial advisor role on BOSS Zhipin's (BOSS直聘) NASDAQ IPO (2021), PatPat's $510M Series D, and Star Ring Technology's (星环科技) STAR Market listing.

The firm operates a hybrid advisory-investor business model across three core service lines. The Investment Banking Services (投行服务) arm provides exclusive financial advisory for funding rounds and IPO/M&A mandates. The Investment Services (投资服务) arm deploys capital directly through the Index AI Industry Innovation Fund (指数人工智能产业创新基金), enabling Index Capital to participate as a principal investor alongside its advisory mandates - evidenced by direct participation in BioGeometry's (百奥几何) strategic round in June 2026. The Industry Insights (指数思考) platform publishes research and thought leadership content across emerging tech verticals, functioning as a top-of-funnel brand-building channel. Revenue is generated primarily through professional-services advisory fees, supplemented by management fees and potential carried interest from the firm's own investment fund. The client base centers on innovative technology enterprises across consumer internet, enterprise SaaS, AI-for-Science, biotech, and hard-tech, with notable repeat clients including Deep Intelligent Pharma (深度智耀, $150M+ cumulative advised financing). The firm has expanded operating geographies beyond China into Japan, the United States, and Singapore, supporting cross-border financings and Chinese-tech-company internationalization.

Short descriptiontext

Index Capital is a China-based boutique full-stack investment bank founded in 2014, providing financial advisory, M&A, and direct investment services to innovative technology companies across AI, biotech, quantum computing, and semiconductors, with 100+ completed financing transactions since inception.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
investment banking advisory, financing advisory services, mergers and acquisitions, venture capital advisory, private equity placement
Industry5 codes
1Capital Raising Advisory (Debt/Equity/Private Capital)
CodeBPAHADAGPrimaryYes
2Equity Capital Advisory (Private Equity Placements, Growth Capital)
CodeBPAHAOAEPrimaryNo
3Corporate Finance & Capital Advisory
CodeBPAHADABPrimaryNo
4Equity Capital Markets Advisory (Equity Issuance Strategy & Readiness)
CodeFSACAAAIPrimaryNo
5Capital Raising Advisory (Equity & Equity-Linked)
CodeFSAEAGACPrimaryNo
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Investment Banking and Financial Advisory Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Financial Advisory (FA) Services
TypeProfessional Services
Description

Index Capital generates revenue by serving as the exclusive financial advisor for companies seeking financing rounds. They assist with strategy formulation, transaction materials preparation, investor matching, and transaction process management. The firm acts as a bridge between innovative enterprises and capital markets.

indexvc.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Index Capital operates as a full-stack investment bank (全栈投行) providing exclusive financial advisory services to innovative technology enterprises across China. The firm assists companies in strategy formulation, transaction material preparation, investor matching, and transaction execution for financing rounds, M&A transactions, and IPO advisory. Index Capital also participates as a direct investor through its own fund and publishes sector research and thought leadership content covering AI, biotech, quantum computing, semiconductors, and new energy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100+ completed financing transactions
+1 more record
Product overview1 text field

Index Capital operates as a full-stack investment bank (全栈投行) providing integrated financial advisory and investment services to innovative technology companies in China. The firm offers investment banking advisory services for funding rounds (投行服务), direct investment through its own fund (投资服务), and industry research/thought leadership content (指数思考). The company focuses on technology sectors including AI, semiconductors, biotech, new energy, and advanced manufacturing. As an organization-empowering investment bank, Index Capital positions itself as a Chief Growth Officer (CGO) partner for client companies, supporting their exponential growth throughout the capital market journey.

Product and service3 records
1投行服务 (Investment Banking Services)
CategoryInvestment Banking Advisory
Description

Full-stack investment banking services providing exclusive financial advisory for technology companies, including funding rounds (Series A through D+), M&A transactions, and strategic capital market advice. Index Capital serves as the exclusive financial advisor, supporting strategy formulation, transaction material preparation, investor matching, and execution. Clients include AI, biotech, quantum computing, semiconductor, and new energy companies such as BOSS Zhipin (BOSS直聘), Deep Intelligent Pharma (DIP), PatPat, Star Ring Technology (星环科技), and Yuanxin Technology (圆心科技).

2投资服务 (Investment Services)
CategoryDirect Investment / Venture Capital
Description

Direct investment services provided through Index Capital's own investment fund, including the Index AI Industry Innovation Fund (指数人工智能产业创新基金). Index Capital participates as an investor in funding rounds of companies it advises, including portfolio companies such as BOSS Zhipin, Yuanxin Technology, Patsnap (智慧芽), Neerbao (奈尔宝), and BioGeometry (百奥几何).

3指数思考 (Index Insights)
CategoryResearch and Thought Leadership
Description

Research and thought leadership content providing market intelligence and investment perspectives on technology sectors including AI, semiconductors, new energy, biotech, and the low-altitude economy. Published as Index Insights (指数洞察) reports and distributed via the Index Capital website.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China's leading publicly listed boutique investment bank focused on TMT, healthcare, and new economy sectors. Closest comparable to Index Capital given overlapping FA-plus-investment model, client base in Chinese tech unicorns, and reputation as a founder-side advisor.

TypeDirect peer
Description

Boutique Chinese FA firm specializing in financing and M&A advisory for TMT and new economy companies. Comparable to Index Capital in deal type, sector focus, and mid-sized boutique operating model.

TypeDirect peer
Description

Boutique Chinese FA firm focused on growth-stage tech, AI, and consumer companies. Directly comparable given its emphasis on FA services for Chinese new-economy issuers, similar in scale and sector coverage.

TypeDirect peer
Description

Boutique Chinese FA firm with deep TMT and healthcare focus. Comparable to Index Capital for its sector concentration in Chinese tech/healthcare growth-stage advisory.

5Duowei Capital (多维资本)
TypeDirect peer
Description

Boutique Chinese FA firm providing growth-stage financing advisory primarily to tech and consumer companies. Comparable scale, deal type, and Chinese new-economy client base.

6Mumian Capital (穆棉资本)
TypeDirect peer
Description

Boutique Chinese FA firm with focus on consumer, TMT, and growth-stage companies. Comparable in boutique positioning and new-economy client base.

TypeBroad incumbent
Description

China's leading full-service investment bank with significant ECM and tech-sector coverage. Comparable as competitor in Chinese tech FA mandates but with much broader service portfolio and balance sheet.

TypeBroad incumbent
Description

Largest Chinese full-service investment bank. Overlaps with Index Capital in ECM advisory for tech issuers and IPO sponsorship, but operates at substantially greater scale and scope.

TypeEmerging player
Description

Asia-focused growth and buyout PE firm. Comparable in Chinese growth-stage deal activity and LP/investor network overlap, though primarily a principal investor rather than FA advisor.

TypeOthers
Description

Top-tier Chinese VC firm that Index Capital actively works with as an investor counterparty. Relevant ecosystem participant and a likely repeat counterparty in client financing rounds, not a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Index Capital

Investment Banking and Financial Advisory Servicesindexvc.com

Index Capital is a China-based boutique full-stack investment bank founded in 2014, providing financial advisory, M&A, and direct investment services to innovative technology companies across AI, biotech, quantum computing, and semiconductors, with 100+ completed financing transactions since inception.

What Index Capital does

Index Capital (指数资本) is a China-based boutique full-stack investment bank (投行) founded in 2014 and headquartered in Shanghai with a regional office in Beijing. The firm provides financial advisory services to innovative technology enterprises, specializing in financing rounds, M&A transactions, IPO advisory, and debt financing. Across sectors including AI, biotech, quantum computing, semiconductors, advanced manufacturing, new energy, and the low-altitude economy, the firm has completed over 100 financing transactions since 2018. Notable mandates include the exclusive financial advisor role on BOSS Zhipin's (BOSS直聘) NASDAQ IPO (2021), PatPat's $510M Series D, and Star Ring Technology's (星环科技) STAR Market listing.

The firm operates a hybrid advisory-investor business model across three core service lines. The Investment Banking Services (投行服务) arm provides exclusive financial advisory for funding rounds and IPO/M&A mandates. The Investment Services (投资服务) arm deploys capital directly through the Index AI Industry Innovation Fund (指数人工智能产业创新基金), enabling Index Capital to participate as a principal investor alongside its advisory mandates - evidenced by direct participation in BioGeometry's (百奥几何) strategic round in June 2026. The Industry Insights (指数思考) platform publishes research and thought leadership content across emerging tech verticals, functioning as a top-of-funnel brand-building channel. Revenue is generated primarily through professional-services advisory fees, supplemented by management fees and potential carried interest from the firm's own investment fund. The client base centers on innovative technology enterprises across consumer internet, enterprise SaaS, AI-for-Science, biotech, and hard-tech, with notable repeat clients including Deep Intelligent Pharma (深度智耀, $150M+ cumulative advised financing). The firm has expanded operating geographies beyond China into Japan, the United States, and Singapore, supporting cross-border financings and Chinese-tech-company internationalization.

Index Capital firmographics

Firmographics
Name
Index Capital
Legal name
指数资本
Website
https://indexvc.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Index Capital is a China-based boutique full-stack investment bank founded in 2014, providing financial advisory, M&A, and direct investment services to innovative technology companies across AI, biotech, quantum computing, and semiconductors, with 100+ completed financing transactions since inception.
Ownership category
akta.pro rank

Index Capital industry classification

Industry
Product category
Investment Banking and Financial Advisory Services
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro primary industry
Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG)
akta.pro secondary industries
Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Corporate Finance & Capital Advisory (BPAHADAB), Equity Capital Markets Advisory (Equity Issuance Strategy & Readiness) (FSACAAAI), Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)

Keywords

  • Investment banking advisory
  • Financing advisory services
  • Mergers and acquisitions
  • Venture capital advisory
  • Private equity placement

Where Index Capital is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Index Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Financial Advisory (FA) Services: Index Capital generates revenue by serving as the exclusive financial advisor for companies seeking financing rounds. They assist with strategy formulation, transaction materials preparation, investor matching, and transaction process management. The firm acts as a bridge between innovative enterprises and capital markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Index Capital product offering

Product offering

Core offering

Index Capital operates as a full-stack investment bank (全栈投行) providing exclusive financial advisory services to innovative technology enterprises across China. The firm assists companies in strategy formulation, transaction material preparation, investor matching, and transaction execution for financing rounds, M&A transactions, and IPO advisory. Index Capital also participates as a direct investor through its own fund and publishes sector research and thought leadership content covering AI, biotech, quantum computing, semiconductors, and new energy.

Product overview

Index Capital operates as a full-stack investment bank (全栈投行) providing integrated financial advisory and investment services to innovative technology companies in China. The firm offers investment banking advisory services for funding rounds (投行服务), direct investment through its own fund (投资服务), and industry research/thought leadership content (指数思考). The company focuses on technology sectors including AI, semiconductors, biotech, new energy, and advanced manufacturing. As an organization-empowering investment bank, Index Capital positions itself as a Chief Growth Officer (CGO) partner for client companies, supporting their exponential growth throughout the capital market journey.

Differentiator

Problem solved

Functional benefit

Products and services

  • 投行服务 (Investment Banking Services) Full-stack investment banking services providing exclusive financial advisory for technology companies, including funding rounds (Series A through D+), M&A transactions, and strategic capital market advice. Index Capital serves as the exclusive financial advisor, supporting strategy formulation, transaction material preparation, investor matching, and execution. Clients include AI, biotech, quantum computing, semiconductor, and new energy companies such as BOSS Zhipin (BOSS直聘), Deep Intelligent Pharma (DIP), PatPat, Star Ring Technology (星环科技), and Yuanxin Technology (圆心科技).
  • 投资服务 (Investment Services) Direct investment services provided through Index Capital's own investment fund, including the Index AI Industry Innovation Fund (指数人工智能产业创新基金). Index Capital participates as an investor in funding rounds of companies it advises, including portfolio companies such as BOSS Zhipin, Yuanxin Technology, Patsnap (智慧芽), Neerbao (奈尔宝), and BioGeometry (百奥几何).
  • 指数思考 (Index Insights) Research and thought leadership content providing market intelligence and investment perspectives on technology sectors including AI, semiconductors, new energy, biotech, and the low-altitude economy. Published as Index Insights (指数洞察) reports and distributed via the Index Capital website.

Quantifiable outcome

  • 100+ completed financing transactions
  • +1 more outcomes

Companies that use Index Capital

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Index Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Index Capital partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Index Capital competitors and assessment

Company assessment

Direct peers

  • China Renaissance (华兴资本): China's leading publicly listed boutique investment bank focused on TMT, healthcare, and new economy sectors. Closest comparable to Index Capital given overlapping FA-plus-investment model, client base in Chinese tech unicorns, and reputation as a founder-side advisor.
  • Hina Group (汉能投资): Boutique Chinese FA firm specializing in financing and M&A advisory for TMT and new economy companies. Comparable to Index Capital in deal type, sector focus, and mid-sized boutique operating model.
  • Lighthouse Capital (光源资本): Boutique Chinese FA firm focused on growth-stage tech, AI, and consumer companies. Directly comparable given its emphasis on FA services for Chinese new-economy issuers, similar in scale and sector coverage.
  • eCapital (易凯资本): Boutique Chinese FA firm with deep TMT and healthcare focus. Comparable to Index Capital for its sector concentration in Chinese tech/healthcare growth-stage advisory.
  • Duowei Capital (多维资本): Boutique Chinese FA firm providing growth-stage financing advisory primarily to tech and consumer companies. Comparable scale, deal type, and Chinese new-economy client base.
  • Mumian Capital (穆棉资本): Boutique Chinese FA firm with focus on consumer, TMT, and growth-stage companies. Comparable in boutique positioning and new-economy client base.

Broad incumbents

  • CICC (中金公司): China's leading full-service investment bank with significant ECM and tech-sector coverage. Comparable as competitor in Chinese tech FA mandates but with much broader service portfolio and balance sheet.
  • CITIC Securities (中信证券): Largest Chinese full-service investment bank. Overlaps with Index Capital in ECM advisory for tech issuers and IPO sponsorship, but operates at substantially greater scale and scope.

Emerging players

  • FountainVest Partners (方源资本): Asia-focused growth and buyout PE firm. Comparable in Chinese growth-stage deal activity and LP/investor network overlap, though primarily a principal investor rather than FA advisor.

Others

  • Qiming Venture Partners (启明创投): Top-tier Chinese VC firm that Index Capital actively works with as an investor counterparty. Relevant ecosystem participant and a likely repeat counterparty in client financing rounds, not a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Index Capital social profiles

Digital presence

Index Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Index Capital leadership team

Management profile

Number of profiles

Index Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Index Capital M&A and investment

M&A and investment

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Index Capital

What does Index Capital do?

Index Capital operates as a full-stack investment bank (全栈投行) providing exclusive financial advisory services to innovative technology enterprises across China. The firm assists companies in strategy formulation, transaction material preparation, investor matching, and transaction execution for financing rounds, M&A transactions, and IPO advisory. Index Capital also participates as a direct investor through its own fund and publishes sector research and thought leadership content covering AI, biotech, quantum computing, semiconductors, and new energy.

Is Index Capital a public or private company?

Index Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Index Capital founded?

Index Capital was founded in 2014. It employs 51 to 100 people.

Where is Index Capital based?

Index Capital is headquartered in Beijing, China, in the Asia region.

How does Index Capital make money?

One revenue line is on record: financial Advisory (FA) Services.

Who are Index Capital's main competitors?

Direct peers on record are China Renaissance (华兴资本), Hina Group (汉能投资), Lighthouse Capital (光源资本), eCapital (易凯资本), Duowei Capital (多维资本) and Mumian Capital (穆棉资本). Broad incumbents are CICC (中金公司) and CITIC Securities (中信证券). FountainVest Partners (方源资本) is listed as an emerging player. Qiming Venture Partners (启明创投) is listed as an others.

Does Index Capital have an API?

No public API is recorded for Index Capital.

What industry is Index Capital in?

Index Capital's product category is Investment Banking and Financial Advisory Services. Its primary akta.pro industry code is BPAHADAG, Capital Raising Advisory (Debt/Equity/Private Capital), with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
JiemianOrigin of the benchmark: Completed three rounds of financing in the past six months, with a total amount reaching hundreds of millions.AlignBase completed three financing rounds in the past six months, raising hundreds of millions from investors including Guoke Investment and Index Capital. The funds will support R&D of core large-model technologies and industrial scenario solutions.JixinChuangrui Spectrum has received over 100 million yuan in Series A financing, with Index Capital continuing to serve as the exclusive financial advisor.Chuangrui Spectrum raised over 100 million yuan in Series A financing, with Index Capital as exclusive financial advisor. The funds will support R&D and capacity expansion, and the company expects large-scale implementation in industrial scenarios in 2025-2026.163"AI pharmaceutical unicorn" Deep Intelligence has received another 280 million yuan in financing.Deep Intelligence Yao (DIP) has completed a $40 million financing round (approximately 276 million RMB), with participation from existing shareholders including Dinghui Baifu, New Ding Capital, Jinyi Capital, and Kaita Capital, while Index Capital served as financial advisor. This marks the company's third financing round within three months, following a $60 million round in February 2026 and a $50 million Series D in December 2025, bringing total recent fundraising to $150 million. The funds will be directed toward developing multi-matrix AGI brain models for life and material sciences, expanding operations in China, Japan, and the United States, and recruiting global AI and science talent.PedailyFocusing on quantum computing, Coherent Technology has completed over 100 million yuan in Pre-A round financing.Xianggan (Beijing) Technology Co., Ltd. has completed a Pre-A round financing exceeding 100 million yuan, with Index Capital serving as the financial advisor. The company, established in 2023 and incubated at the Beijing Quantum Information Science Research Institute, focuses on superconducting quantum computing technology solutions and has already received commercial orders. The funding will accelerate the development of quantum computing systems and expand the company's computing power service business.JiemianXianggan Technology completes over 100 million yuan Pre-A round financingXianggan (Beijing) Technology Co., Ltd. has completed an over 100 million yuan Pre-A round financing, led by Tianji Capital and PwC Capital, with participation from multiple follow-on investors including Beichuang Investment, Bian Era, Yingfu Taike, Qifu Capital, and Binfu Capital. Index Capital served as the financial advisor for the transaction. The company intends to use the proceeds primarily for building quantum computing systems and expanding its talent pool.Fastdata极数北京新药研发服务提供商深度智耀获近5000万美元D轮融资 – Fastdata极数Beijing-based AI-powered drug R&D service provider Deep Intelligent Pharma has secured nearly $50 million in Series D financing. The round was led by DCM with participation from existing investors New Horizon Capital and Sequoia China, while Index Capital served as exclusive financial advisor. The company plans to use the proceeds for technological R&D iteration of its multi-agent collaborative network and construction of a global delivery network.Fastdata极数Xi'an medical isotope product developer Mastech announced the completion of nearly 100 million yuan in angel round financing - Fastdata.Xi'an-based Mastech Topology, a high-tech company specializing in medical isotopes and nuclear medicine equipment, announced the completion of a nearly 100 million yuan angel round financing led by Zhongke Chuangxing, with participation from Shurichengxing, Zhengjing Capital, and Index Capital as exclusive financial advisor. The funding will primarily support the construction and installation of the company's medical isotope production base in Mianyang, with the goal of achieving commercial supply of innovative alpha and beta nuclides including Ac-225, Pb-212, and Cu-67 by the end of 2026.Fastdata极数北京3D打印解决方案服务商清锋科技完成新一轮融资 – Fastdata极数Qingfeng Technology, a Beijing-based 3D printing and software development service provider, has completed a new round of financing strategically invested by Times Angel, with Index Capital serving as the exclusive financial advisor. The company focuses on ultra-fast 3D printing technology and offers services including software development, electronic hardware development, and material development aimed at improving manufacturing efficiency and reducing production costs for enterprises.ToutiaoRansai Intelligent has received tens of millions in Pre-B round financing, deeply cultivating 3D printing in dentistry.Ransai Intelligent (also referred to as Laisai Intelligent) has received tens of millions in Pre-B round financing, with Index Capital serving as financial advisor for the round. The funding is directed toward 3D printing applications in dentistry, positioning the company to expand from processing facilities into chairside clinical treatment and international markets. The financing reflects investor confidence in dental 3D printing as a leading commercial application within AI-driven healthcare transformation.PedailyKomei Technology has completed tens of millions in Pre-A round financing, led by Xichuang Investment and followed by Jiayi Investment.Carcell Biopharma completed a Pre-A financing round of tens of millions RMB, led by Xichuang Capital with participation from Jia Yi Investment and Index Capital as financial advisor. The funds will be used to advance IIT clinical trials for red blood cell products and expedite IND filings while continuing the development of its lipid nanoparticle platform. This investment supports the company's strategy to leverage its dual technology platforms for drug delivery in autoimmune diseases and nucleic acid therapies.